It is considered to expand the database and for this purpose there was a survey among the members about the priority of the possible additional information suche as Volume information, MEA, further price regulated products or Medical devices should and can be included in the database. The survey is still ongoing.
The 4th Meeting of the Stakeholder Dialogue Platform on Pricing of Medicinal Products will take place on Tuesday, 11 May 2021, 10.00-12.00 am.
Here you find the event Link (WebEx):
https://neak.webex.com/neak-en/j.php?MTID=m18db35996f517b30a915b7638cfb71c5
You can download the agenda here.
Finally the time has come and our official website is online. You can find all necessary information regarding the EURIPID project on this website. It should give an overview of the organization and the content of the project. The new website includes a newsletter function also. This newsletter will contain news from and beyond our project. It’s best to register now!
A recent survey among Euripid members confirmed their interest in sharing not only concrete price information but also information on the application of Managed Entry Agreements for individual products. Currently, 13 countries share information on MEAs for all or selected products. Another priority that was recently confirmed by members is the provision of volume information. Since January 2021, eleven countries share this information on the platform, partly dating back to 2015. The Secretariat is working on integrating information from a few more countries.
Further priorities of members include information on prices of non-reimbursed medicines or their patent status.
Also all but one respondent confirmed that they are either satisfied or very satisfied with the current form of the database.
Adopted on 25 November 2020, the Pharmaceutical Strategy for Europe aims at creating a future proof regulatory framework and at supporting industry in promoting research and technologies that actually reach patients in order to fulfil their therapeutic needs while addressing market failures.
The 3rd Fair Pricing Forum took place online from 13-22 April 2021 and focused again on improving access to medicines and health products through fair pricing, following the inaugural forum held in the Netherlands in 2017 (10–11 May) and the second forum in South Africa in 2019 (11-13 April). WHO invited the Euripid Collaboration to present our work. The presentation gives an overview of the collaboration and the project and outlines Euripid activities in improving access to medicines. An important information is that all countries from the WHO Euro Region may apply for membership.
In the light of the WHA resolution in 2019 on improving transparency in the medicines’ market, the EURIPID Executive Committee launched a survey to explore feasible options to foster information exchange and cross-country collaboration in this field.
The survey focused on high-cost and on-patent medicines, for which the sharing of price information is potentially more relevant.
The result were presented by the Italian Medicines Agency AIFA in September 2020.
